SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt) Operating Income

As of the most recent data (June 2026), BCYPU shows a operating income of $-72M. That compares with $-36M in the prior-year period — down 98.6% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BCYPU's operating income is now $-72M (was $-36M) — a 98.6% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt) is outperforming or lagging.

Tracking BCYPU's operating income over time shows whether SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt) is scaling, shrinking, or reshaping that part of the business. The current reading is $-72M That compares with $-36M in the prior-year period — down 98.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $-72M) with ownership activity and broader fundamentals.